COMP <GO>
PBYI vs UNH // REVENUE GROWTH (YOY)
Puma Biotechnology Inc (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: PBYI 7
— UNH 6
▲ REVENUE GROWTH (YOY) LEADER: UNH
LAST: $10.44 (-0.95%) • MKT CAP: $544.1M
revenue-growth
-0.90%
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBYI VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBYI | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 88.57% | -14.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.30% | 11.47% | +17.83 | PBYI | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 16.4x | -2.65 | PBYI | /valuation <GO> |
| Free Cash Flow Yield | 7.67% | 6.48% | +1.19 | PBYI | /fcf-yield <GO> |
| Operating Margin | 16.30% | 4.82% | +11.48 | PBYI | /operating-margins <GO> |
| Net Profit Margin | 13.60% | 3.14% | +10.46 | PBYI | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -0.90% | 6.46% | -7.36 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.12 | -2.92 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PBYI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 59.2 | -4.70 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.3x | 17.7x | -1.44 | PBYI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $544.1M | $368.83B | -$368.29B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBYI REV | UNH REV | PBYI GROSS % | UNH GROSS % | PBYI FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.4M | $447.57B | 74.5% | 88.7% | $41.7M | $16.07B |
| FY 2024 | $230.5M | $400.28B | 72.1% | 88.3% | $38.9M | $20.70B |
| FY 2023 | $235.6M | $371.62B | — | 89.6% | $27.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBYI // BETA —
UNH // BETA 0.33